5224 Investors following Dishman Pharma. Share this News with them.
0
Like this story, share it with millions of investors on M3
Dishman Pharma an outperformer: Karvy
Karvy Stock Broking has downgraded its rating on Dishman Pharmaceuticals & Chemicals from buy to outperformer with a target of Rs 380. The research firm expects revenues and earnings to grow at a CAGR of 31.4% and 27% from FY08 to FY10E driven primarily from the high margin CRAMS segment.
Karvy Stock Broking has downgraded its rating on Dishman Pharmaceuticals & Chemicals from buy to outperformer with a target of Rs 380 in its September 19, 2008 research report. "We expect revenues and earnings to grow at a CAGR of 31.4% and 27% from FY08 to FY10E driven primarily from the high margin CRAMS segment. The stock is currently available at P/E of 18.3x on FY09E diluted EPS of Rs 17.1 and P/E of 13.3x on FY10E diluted EPS of Rs 23.6. We maintain our long term positive outlook on the company and our price target of Rs 380 based on P/E of 16.1x FY10E. We however downgrade our recommendation from 'BUY' to 'Outperformer' on back of 5.4% increase in stock price since our last update," says Karvy Stock Broking's research report.
Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
To read the full report click on the attachment......
